GH Research (GHRS) Cash from Investing Activities (2021 - 2025)
GH Research (GHRS) recorded quarterly Cash from Investing Activities of $8.8 million in Q4 2025, down 9.65% quarter-over-quarter from $9.8 million in Q3 2025, and down 58.56% on a YoY basis from $21.3 million in Q4 2024.
GH Research (GHRS) Cash from Investing Activities (2021 - 2025) Analysis & Trends
GH Research's Cash from Investing Activities history runs 5 years deep, the most recent figure standing at $8.8 million for Q4 2025.
- In Q4 2025, Cash from Investing Activities fell 58.56% year-over-year to $8.8 million; the TTM figure through Dec 2025 stood at $46.2 million (down 29.11% YoY), while the FY2025 annual figure was $46.2 million, down 29.11% from the prior year.
- Cash from Investing Activities was $8.8 million for Q4 2025 at GH Research, down from $9.8 million in the prior quarter.
- In the past five years, Cash from Investing Activities ranged from a high of $21.3 million in Q4 2024 to a low of -$84.6 million in Q4 2022.
- Historically, Cash from Investing Activities has averaged -$1.4 million across 5 years, with a median of -$12000.0 in 2021.
- The sharpest annual moves came in 2023 and 2024: Cash from Investing Activities tumbled 540120.0% in 2023, then jumped 191150.0% in 2024.
- A 5-year view of Cash from Investing Activities shows it stood at -$19000.0 in 2021, then slumped by 445368.42% to -$84.6 million in 2022, then jumped by 99.97% to -$24000.0 in 2023, then jumped by 88979.17% to $21.3 million in 2024, then plunged by 58.56% to $8.8 million in 2025.
- The last three Cash from Investing Activities figures came in at $8.8 million (Q4 2025), $9.8 million (Q3 2025), and $15.7 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | - |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | - |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | -2.89 Mn |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | 638.50 Mn |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | - |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | -431.90 Mn |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | 579,519.10 |
| 10 | GH Research | 9.73 Bn | 9.63 Bn | - | 8.84 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 8.84 Mn |
| Dec 31, 2025 | 8.84 Mn |
| Sep 30, 2025 | 9.78 Mn |
| Sep 30, 2025 | 9.78 Mn |
| Jun 30, 2025 | 15.71 Mn |
| Jun 30, 2025 | 15.71 Mn |
| Mar 31, 2025 | 11.84 Mn |
| Mar 31, 2025 | 11.84 Mn |
| Dec 31, 2024 | 21.33 Mn |
| Dec 31, 2024 | 21.33 Mn |
| Sep 30, 2024 | 15.28 Mn |
| Sep 30, 2024 | 15.28 Mn |
| Jun 30, 2024 | 19.73 Mn |
| Jun 30, 2024 | 19.73 Mn |
| Mar 31, 2024 | 8.79 Mn |
| Mar 31, 2024 | 8.79 Mn |
| Dec 31, 2023 | -24,000.00 |
| Dec 31, 2023 | -24,000.00 |
| Sep 30, 2023 | -8,000.00 |
| Sep 30, 2023 | -8,000.00 |